Skip to main content

Table 3 Characteristics of the 20 interviewees

From: Patients’ high acceptability of a future therapeutic HIV vaccine in France: a French paradox?

Patient Gender M/F Duration of HIV diagnosis CDC ART ART regimen
1 F 17 A RAL/LPV BID
2 M 23 A TDF/FTC/DRV/r OD
3 M 18 C TDF/FTC/EFV OD
4 M 32 A TDF/FTC/RAL BID
5 M 9 C TDF/FTC/EFV OD
6 M 6 A TDF/FTC/RPV OD
7 F 35 A TDF/FTC/RAL OD
8 M 32 C TDF/FTC/DRV/r OD
9 M 25 A TDF/FTC OD
10 M 33 A ABC/3TC/EFV OD
11 M 14 A TDF/FTC/ETR OD
12 M 7 A TDF/FTC/RPV OD
13 F 33 A TDF/FTC/DRV/r OD
14 F 18 C TDF/FTC/LPV/r BID
15 M 34 B ABC/3TC/EFV OD
16 M 32 A TDF/FTC/DRV/r BID
17 M 33 C TDF/FTC/DRV/r BID
18 F 22 A ABC/3TC/ETV OD
19 F 9 A DRV/r OD
20 F 7 A TDF/FTC/EFV OD
  1. Abbreviations: ART active antiretroviral therapy, 3TC lamivudine, FTC emtricitabine, ABC abacavir, TDF tenofovir, ETV etravirine, RPV rilpivirine, EFV efavirenz, DRV darunavir, LPV lopinavir, r ritonavir, RAL raltegravir, OD once a day, BID twice a day